KEYNOTE-789 / CheckMate 722：EGFR-TKI 后 PD-1 + 化疗的阴性 III 期证据
类型: III期临床试验 / 免疫治疗 发表日期: 2024-08-22 入库日期: 2026-05-21 来源: PubMed / Journal of Clinical Oncology 标签: EGFR L858R, 免疫治疗, Pembrolizumab, Nivolumab, KEYNOTE-789, CheckMate 722, 奥希替尼后, 化疗
Citations
Yang JC, et al. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. Journal of Clinical Oncology. 2024. PMID: 39173098. DOI: 10.1200/JCO.23.02747
Mok TSK, et al. Nivolumab Plus Chemotherapy in EGFR-Mutated Metastatic NSCLC After Disease Progression on EGFR TKIs: Final Results of CheckMate 722. Journal of Clinical Oncology. 2024. PMID: 38252907. DOI: 10.1200/JCO.23.01017
Why it matters for mom
Mom has EGFR L858R metastatic NSCLC and has received osimertinib plus platinum/pemetrexed-style therapy. These two randomized phase III trials are important because they test a tempting question: whether simply adding a PD-1 inhibitor to standard platinum/pemetrexed chemotherapy after EGFR-TKI resistance improves outcomes.
The broad answer from these trials is cautionary: PD-1 plus chemotherapy did not clearly become the default answer for EGFR-mutant disease after EGFR-TKI progression.
Practical takeaways
- Immunotherapy should not be assumed to work like it does in EGFR-wild-type NSCLC.
- Pembrolizumab/nivolumab plus platinum/pemetrexed alone is not the same evidence category as chemo + anti-VEGF + immunotherapy regimens.
- If immunotherapy is proposed, ask what exact regimen, evidence base, line of therapy, PD-L1/TMB context, and toxicity/sequencing plan support it.
- Be especially alert to lung toxicity/pneumonitis discussions when immune checkpoint inhibitors and EGFR TKIs are used near each other.
Questions for doctors
- In her exact EGFR L858R context, is immunotherapy being considered because of standard evidence, trial access, high PD-L1/TMB, transformation, or lack of alternatives?
- Would immunotherapy require stopping osimertinib, and what washout or pneumonitis precautions are needed?
- If the goal is post-osimertinib disease control, why not prioritize repeat biopsy/NGS and EGFR-specific options first?